osk的部落格

ALK抑製劑

Survey 調查 of ALK inhibitors effects 效果 on brain mets.

This survey summarizes the results of other research to describe the current level of knowledge about

how effective different ALK inhibitors are at treating brain mets.

Inhibitors that are discussed include crizotinib, ceritinib, alectinib, AP26113 (brigatinib) and PF-06463922 (lorlatinib).

http://www.thecco.net/article/view/6520/7543

****************************************************************

Editorial 社論 on Brain mets and ALK lung cancer

The Journal of Clinical Oncology has an editorial about the current research on treating brain mets for ALK+ patients

that discusses ALK inhibitors and different kinds of radiation treatments.

Treatments discussed include:

1) Crizotinib, 2) Ceritinib 3) Alectinib 4) brigatinib, 5) PF-06463922, 6) whole brain radiation (WBR),

7) stereo static radiation (SRS), 8) radiation with memantine, and 9) radiation with hippocampal avoidance.

Conclusions 結論 and suggested research include:

1) avoiding WBR if there are 10 or less brain mets,

2) using ALK inhibitors that enter the brain as long as possible,

3) trials to test optimal combinations, timing, and sequencing of all these treatment options,

4) ALK + patients with brain mets that are treated with ALK inhibitors live notably longer than patients with brain mets seen in historical trials of lung cancer patients with brain mets and thus new recomended treatment protocols should be tested and tolerable side effects reevaluated,

5) about 30% of ALK + patients initially present with brain mets and up to 60% of patients treated with Crizotinib develop brain mets, and

6) both the use of memantine and the avoidance of the hippocampus appear to minimize the cognitive side effects of radiation treatment.

http://jco.ascopubs.org/content/early/2015/11/30/JCO.2015.63.9682.full.pdf

A related 相關 research paper 研究論文 is described below on October 22 under “ALK and brain mets”.

****************************************************************

Posted by Dr. Guneet Walia on September 18th, 2015

Data on 3 promising 有希望的 ALK inhibitors was presented 提交 at the recently concluded 最近結束16th World Conference

第16屆世界大會 on Lung Cancer (WCLC) in Denver, CO in which the Addario Lung Cancer Foundation基金會

participated 參加 - Alectinib, Brigatinib and Loralitinib.